Published in Anticancer Res on May 01, 2014
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
Results of the European Glaucoma Prevention Study. Ophthalmology (2005) 2.91
Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol (2013) 2.84
Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol (2014) 2.81
Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. Am J Ophthalmol (2007) 2.73
Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res (2007) 2.54
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol (2009) 2.47
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst (2007) 2.42
Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology (2006) 2.28
Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol (2011) 2.27
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst (2003) 2.14
Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology (2006) 2.01
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst (2008) 1.92
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst (2003) 1.75
Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev (2009) 1.63
High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology (2009) 1.53
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer (2011) 1.48
Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging (2010) 1.48
Dual modulation of MCL-1 and mTOR determines the response to sunitinib. J Clin Invest (2016) 1.47
Differentiation of small adnexal masses based on morphologic characteristics of transvaginal sonographic imaging: a multicenter study. J Ultrasound Med (2005) 1.46
Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma. J Natl Cancer Inst (2004) 1.39
Update on the treatment of neuroendocrine tumors. Expert Rev Anticancer Ther (2003) 1.33
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Cancer (2012) 1.30
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol (2006) 1.28
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int (2011) 1.24
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol (2005) 1.14
To target or not to target, that is the question. J Clin Oncol (2013) 1.12
Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. Int J Cancer (2006) 1.11
The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU Int (2012) 1.11
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations? J Clin Oncol (2014) 1.09
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis (2010) 1.09
Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Rev Anticancer Ther (2011) 1.09
Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer Res (2014) 1.08
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. Clin Exp Nephrol (2012) 1.06
Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial. Int J Radiat Oncol Biol Phys (2003) 1.06
The European glaucoma prevention study design and baseline description of the participants. Ophthalmology (2002) 1.05
Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One (2012) 1.05
Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab (2009) 1.04
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer (2006) 1.04
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer (2010) 1.03
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. Cancer Treat Rev (2012) 1.03
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol (2014) 1.00
Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res (2008) 1.00
Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. Clin Genitourin Cancer (2013) 0.97
Maintenance or consolidation therapy in small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer (2010) 0.96
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev (2015) 0.96
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. Clin Cancer Res (2004) 0.96
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. J Clin Pathol (2011) 0.94
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104). Int J Cancer (2013) 0.94
Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. Health Qual Life Outcomes (2006) 0.93
Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One (2011) 0.92
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int (2012) 0.92
Cost of insurance policies for investigator-initiated cancer clinical trials in Italy. Tumori (2005) 0.92
Autoimmune disorders in patients affected by celiac sprue and inflammatory bowel disease. Ann Med (2009) 0.91
Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res (2009) 0.90
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study. Oncology (2007) 0.90
In regard to Kagan: "The multidisciplinary clinic" (Int J Radiat Oncol Biol Phys 2005;61:967-968). Int J Radiat Oncol Biol Phys (2005) 0.90
Central corneal thickness in the European Glaucoma Prevention Study. Ophthalmology (2006) 0.89
SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J Proteomics (2012) 0.89
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol (2014) 0.89
Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori (2005) 0.89
Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther (2012) 0.88
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Curr Drug Targets (2015) 0.87
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert Opin Drug Saf (2014) 0.87
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. Am J Clin Oncol (2015) 0.87
Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. Spine (Phila Pa 1976) (2016) 0.87
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol (2013) 0.85
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology (2008) 0.84
ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am J Cancer Res (2013) 0.83
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer (2014) 0.83
Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. Future Oncol (2014) 0.82
Abiraterone acetate in castration-resistant prostate cancer. Anticancer Drugs (2012) 0.82
Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer. Tumori (2009) 0.82
Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer. Invest New Drugs (2008) 0.82
Experience with sorafenib in the treatment of advanced renal cell carcinoma. Ther Adv Urol (2012) 0.82
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. BJU Int (2014) 0.82